Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy
暂无分享,去创建一个
Jonathan Alvarsson | Rolf Larsson | Claes R. Andersson | Claes R Andersson | Peter Nygren | K. Blom | C. Andersson | R. Larsson | P. Nygren | Kristin Blom | Jonathan Alvarsson
[1] J. Bergh,et al. Detection of tumor‐specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients , 1994, International journal of cancer.
[2] R. Larsson,et al. Predictive tests for individualization of pharmacological cancer treatment. , 2008, Expert opinion on medical diagnostics.
[3] Lippman Me,et al. Clonogenic and nonclonogenic in vitro chemosensitivity assays , 1985 .
[4] R. Larsson,et al. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). , 1994, Gynecologic oncology.
[5] Ola Spjuth,et al. Brunn: An open source laboratory information system for microplates with a graphical plate layout design process , 2011, BMC Bioinformatics.
[6] J. Sierra,et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. , 2014, Clinical lymphoma, myeloma & leukemia.
[7] A. G. Bosanquet. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay , 1991, The Lancet.
[8] Krister Wennerberg,et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.
[9] Peter Nygren,et al. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) , 1992, International journal of cancer.
[10] R. Larsson,et al. In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA) , 1997, International journal of cancer.
[11] J. Bergh,et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Larsson,et al. Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia. , 1993, European journal of cancer.
[13] Sridhar Ramaswamy,et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.
[14] L. Weisenthal,et al. Clonogenic and nonclonogenic in vitro chemosensitivity assays. , 1985, Cancer treatment reports.
[15] R. Larsson,et al. In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). , 1993, British Journal of Cancer.